Low-grade serous carcinoma: New concepts and emerging therapies

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 660-666

  Romero, Ignacio ^a,b   Sun, Charlotte C ^a   Wong, Kwong K ^a   Bast, Robert C ^a   Gershenson, David M ^a  

^a not available

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Low grade serous; MAP kinase; MEK inhibitor; Ovarian cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; SELUMETINIB; TRAMETINIB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA; COPY NUMBER VARIATION; CYTOREDUCTIVE SURGERY; GENE DOSAGE; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; INVASIVE CARCINOMA; MULTIMODALITY CANCER THERAPY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA;

EID: 84882453525     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.021     Document Type: Review

References (98)

1. M.A. Bookman, M.F. Brady, and W.P. McGuire Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 9 2009 1419 1425
2. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
3. G.C. Stuart, H. Kitchener, and M. Bacon 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21 4 2011 750 755
4. K.M. Schmeler, and D.M. Gershenson Low-grade serous ovarian cancer: a unique disease Curr Oncol Rep 10 6 2008 519 523
5. D.M. Gershenson The heterogeneity of epithelial ovarian cancer: getting it right Cancer 116 6 2010 1400 1402
6. P.P. Koonings, K. Campbell, and D.R. Mishell Jr. Relative frequency of primary ovarian neoplasms: a 10-year review Obstet Gynecol 74 1989 921 926
7. J.D. Seidman, I. Horkayne-Szakaly, and M. Haiba The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin Int J Gynecol Pathol 23 2004 41 44
8. E.G. Silva, S.S. Robey-Cafferty, T.L. Smith, and D.M. Gershenson Ovarian carcinomas with transitional cell carcinoma pattern Am J Clin Pathol 93 4 1990 457 465
9. J.H. Eichhorn, and R.H. Young Transitional cell carcinoma of the ovary: a morphologic study with emphasis on differential diagnosis Am J Surg Pathol 28 2004 453 463
10. S.G. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 2000 7 15
11. International Federation of Gynecology and Obstetrics (FIGO) Classification and staging of malignant tumors in the female pelvis Acta Obstet Gynecol Scand 50 1971 1 7
12. K.R. Lee, F.A. Tavassoli, and J. Prat Surface epithelial-stromal tumors: serous tumors R.E. Scully, in collaboration with Sobin LH and pathologists from 5 countries. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs 2003 IARC Press Lyon 117 161
13. P. Russell, S.J. Robboy, and M.C. Anderson Epithelial/stromal tumors: serous tumors S.J. Robboy, M.C. Anderson, Pathology of the female reproductive tract 2002 Churchill Livingstone London 539 605
14. R.E. Scully, R.H. Young, and P.B. Clement Surface epithelial-stromal tumors: serous tumors R.E. Scully, R.H. Young, P.B. Clement, Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament: Atlas of Tumor Pathology, 3rd series, fascicle 23 1998 Armed Forces Institute of Pathology Washington, DC 51 79
15. J.D. Seidman, P. Russell, and R. Kurman Surface epithelial tumors of the ovary R.J. Kurman, Blaunstein's pathology of the female genital tract 5th ed. 2001 Springer-Verlag New York 791 904
16. A. Malpica, M.T. Deavers, and K. Lu Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
17. A. Malpica, M.T. Deavers, and C. Tornos Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma Am J Surg Pathol 31 8 2007 1168 1174
18. Y. Shimizu, S. Kamoi, and S. Amada Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up Cancer 82 1998 893 901
19. J.D. Seidman, I. Horkayne-Szakaly, and J.A. Cosin Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum Gynecol Oncol 103 2 2006 703 708
20. R. Vang, I.-M. Shih, and R. Salani Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data Am J Surg Pathol 32 2008 1667 1674
21. D.C. Bodurka, M.T. Deavers, and C. Tian Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study Cancer 118 2012 3087 3094
22. A. Ayhan, R.J. Kurman, and A. Yemelyanova Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis Am J Surg Pathol 33 8 2009 1220 1224
23. M.A. Crispens, D. Bodurka, and M. Deavers Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential Obstet Gynecol 99 2002 3 10
24. E.G. Silva, M.T. Deavers, and A. Malpica Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae Int J Gynecol Pathol 29 6 2010 507 512
25. F.A. Tavassoli, and P. Devilee Serous tumors. In tumors of the ovary and peritoneum F.A. Tavassoli, P. Devilee, World Health Organisation classification of tumors. Pathology and genetics. Tumors of the breast and female genital organs 2003 IARC Press Lyon 119 124
26. J.D. Seidman, and R.J. Kurman Ovarian serous borderline tumors a critical review of the literature with emphasis on prognostic indicators Hum Pathol 31 2000 539 557
27. T.A. Longacre, J.K. McKenney, and H.D. Tazelaar Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (5-year) follow-up Am J Surg Pathol 29 2005 707 723
28. J.K. McKenney, B.L. Balzer, and T.A. Longacre Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion Am J Surg Pathol 30 10 2006 1209 1221
29. M.S. Lenhard, S. Mitterer, and C. Kumper Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort Eur J Obstet Gynecol Reprod Biol 145 2 2009 189 194
30. R. Hogg, J. Scurry, and S.N. Kim Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma Gynecol Oncol 106 1 2007 44 51
31. R.T. Burks, M.E. Sherman, and R.J. Kurman Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors Am J Surg Pathol 20 1996 1319 1330
32. J.D. Seidman, and R.J. Kurman Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases Am J Surg Pathol 20 1996 1331 1345
33. J.H. Eichhorn, D.A. Bell, and R.H. Young Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns Am J Surg Pathol 23 1999 397 409
34. M.T. Deavers, D.M. Gershenson, and G. Tortolero-Luna Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases Am J Surg Pathol 26 9 2002 1129 1141
35. W. McCluggage The pathology of and controversial aspects of ovarian borderline tumours Curr Opin Oncol 22 5 September 2010 462 472
36. N. Ruiz, J.M. del Campo, and E. Calvo Early stages (I-IIa) epithelial ovarian cancer (EOC): preliminary data of the prospective register of the Spanish Group on Research of Ovarian cancer (GEICO) 2008 ESMO (Abstr.669)
37. M.M. Leitao, J. Boyd, and A. Hummer Clinicopathologic analysis of early-stage sporadic ovarian carcinoma Am J Surg Pathol 28 2004 147 159
38. W.E. Winter 3rd, G.L. Maxwell, and C. Tian Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 24 2007 3621 3627
39. S.C. Plaxe Epidemiology of low-grade serous ovarian cancer Am J Obstet Gynecol 198 2008 459.e1 459.e9
40. D.M. Gershenson, E.G. Silva, and G. Tortolero-Luna Serous borderline tumors of the ovary with noninvasive peritoneal implants Cancer 83 1998 2157 2163
41. D.M. Gershenson, E.G. Silva, and L. Levy Ovarian serous borderline tumors with invasive peritoneal implants Cancer 82 1998 1096 1103
42. E.G. Silva, D.M. Gershenson, and A. Malpica The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent Am J Surg Pathol 11 2006 1367 1371
43. M.A. Rossing, J.R. Daling, and N.S. Weiss Ovarian tumors in a cohort of infertile women N Engl J Med 331 12 1994 771 776
44. F. Parazzini, E. Negri, and C. La Vecchia Treatment for fertility and risk of ovarian tumors of borderline malignancy Gynecol Oncol 68 3 1998 226 228
45. D. Denschlag, M. von Wolff, and F. Amant Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery Gynecol Obstet Invest 70 3 2010 160 165
46. C.Y. Hsu, R. Bristow, and M.S. Cha Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin Cancer Res 10 19 2004 6432 6436
47. G. Singer, R. Oldt 3rd, and Y. Cohen Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 6 2003 484 486
48. D. Mayr, A. Hirschmann, and U. Löhrs KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants Gynecol Oncol 103 3 2006 883 887
49. N.L. Sieben, P. Macropoulos, and G.M. Roemen In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours J Pathol 202 3 2004 336 340
50. G. Singer, R.J. Kurman, and H.W. Chang Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 4 2002 1223 1228
51. G. Singer, IeM Shih, and A. Truskinovsky Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int J Gynecol Pathol 22 1 2003 37 41
52. G. Singer, R. Stöhr, and L. Cope Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2 2005 218 224
53. R.F. Caduff, S.M. Svoboda-Newman, and A.W. Ferguson Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors Am J Surg Pathol 23 3 1999 323 328
54. G. Fabjani, G. Kriegshaeuser, and A. Schuetz Biochip for K-ras mutation screening in ovarian cancer Clin Chem 51 4 2005 784 787
55. V. Auner, G. Kriegshäuser, and D. Tong KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay BMC Cancer 9 2009 111
56. M.G. Teneriello, M. Ebina, and R.I. Linnoila p53 and Ki-ras gene mutations in epithelial ovarian neoplasms Cancer Res 53 13 1993 3103 3108
57. M.S. Anglesio, J.M. Arnold, and J. George Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors Mol Cancer Res 6 11 2008 1678 1690
58. K.K. Wong, Y.T. Tsang, and M.T. Deavers BRAF mutation is rare in advanced-stage low grade ovarian serous carcinomas Am J Pathol 177 4 2010 1611 1617
59. Cancer Genome Atlas Research Network Nature 474 7353 2011 609 615
60. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heel of cancer Science 297 5578 2002 63 64
61. R.N. Grisham, G. Iyer, and K. Garg BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer Cancer 119 2013 548 554
62. Y. Wang, A. Helland, and R. Holm PIK3CA mutations in advanced ovarian carcinomas Hum Mutat 25 3 2005 322
63. S. Jones, T.L. Wang, and R.J. Kurman Low-grade serous carcinomas of the ovary contain very few point mutations J Pathol 226 2012 413 420
64. L.V. Wain, J.A. Armour, and M.D. Tobin Genomic copy number variation, human health, and disease Lancet 374 2009 340 350
65. D.G. Albertson Gene amplification in cancer Trends Genet 22 8 2006 447 455
66. J.P. Zheng, W.R. Robinson, and T. Ehlen Distinction of low-grade from high-grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, 11 and HER-2/neu gene amplification Cancer Res 51 15 1991 4045 4051
67. T. Bonome, J.-Y. Lee, and D.-C. Park Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 22 2005 10602 10612
68. K.T. Kuo, B. Guan, and Y. Feng Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas Cancer Res 69 9 2009 4036 4042
69. A.H. Birch, S.L. Arcand, and K.K. Oros Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low-grade ovarian serous tumours PLoS One 6 2012 e28250
70. I. Meinhold-Heerlein, D. Bauerschlag, and F. Hilpert Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Oncogene 24 2005 1053 1065
71. A.A. Jazaeri, K. Lu, and R. Schmandt Molecular determination of tumor differentiation in papillary serous ovarian carcinoma Mol Carcinog 36 2003 53 59
72. C.J. O'Neill, M.T. Deavers, and A. Malpica An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas Am J Surg Pathol 29 2005 1034 1041
73. K.K. Wong, K.H. Lu, and A. Malpica Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis Int J Gynecol Pathol 26 4 2007 404 409
74. C.S. Tung, S.C. Mok, and Y.T.M. Tsang PAX2 expression in low malignant ovarian tumors and low-grade ovarian serous carcinomas Mod Pathol 22 2009 1243 1250
75. E.R. King, C.S. Tung, and Y.T.M. Tsang The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer Am J Surg Pathol 35 2011 904 912
76. E.R. King, Z. Zu, and Y.T.M. Tsang The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma Gynecol Oncol 123 2011 13 18
77. T. May, C. Virtanen, and M. Sharma Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary Gynecol Oncol 117 2010 9 17
78. H. Naora, and D.J. Montell Ovarian cancer metastasis: integrating insights from disparate model organisms Nat Rev Cancer 5 5 2005 355 366
79. M.F. Fathalla Incessant ovulation - a factor in ovarian neoplasia? Lancet 2 7716 1971 163
80. A. Berchuck, M.F. Kohler, and M.P. Hopkins Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors Gynecol Oncol 52 2 1994 232 236
81. M.J. Callahan, C.P. Crum, and F. Medeiros Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J Clin Oncol 25 2007 3985 3990
82. A. Finch, P. Shaw, and B. Rosen Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers Gynecol Oncol 100 2006 58 64
83. Y. Lee, A. Miron, and R. Drapkin A candidate precursor to serous carcinoma that originates in the distal fallopian tube J Pathol 211 2007 26 35
84. M.A. Vineyard, M.S. Daniels, and D.L. Urbauer Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer? Gynecol Oncol 120 2011 229 232
85. R.J. Kurman, and Ie M. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 2010 433 443
86. J. Li, N. Abushahin, and S. Pang Tubal origin of 'ovarian' low-grade serous carcinoma Mod Pathol 11 2011 1488 1499
87. K. Leonhardt, J. Einenkel, and S. Sohr p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary Int J Gynecol Pathol 30 5 2011 417 424
88. O. Ondic, V. Kalis, and R. Sima Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants J Obstet Gynaecol Res 37 2011 0756 1447
89. N. Auersperg The origin of ovarian carcinomas: a unifying hypothesis Int J Gynecol Pathol 30 1 2011 12 21
90. D.M. Gershenson, C.C. Sun, and K.H. Lu Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary Obstet Gynecol 108 2 2006 361 368
91. K.M. Schmeler, C.C. Sun, and D.C. Bodurka Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 108 3 2008 510 514
92. D.M. Gershenson, C.C. Sun, and D. Bodurka Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol Oncol 114 1 2009 48 52
93. R.E. Bristow, D.R. Gossett, and D.R. Shook Recurrent micropapillary serous carcinoma: the role of secondary cytoreductive surgery Cancer 95 2002 791 800
94. D.M. Gershenson, C.C. Sun, and R. Iyer Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 125 2012 661 666
95. M.P. Schlumbrecht, C.C. Sun, and K.N. Wong Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma Cancer 117 2011 3741 3749
96. J. Farley, W.E. Brady, and V. Vathipadiekal Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study Lancet Oncol 14 2013 134 140
97. J.R. Dry, S. Pavey, and C.A. Pratilas Transcriptional pathway signatures predict MEK addiction and response to Selumetinib (AZD6244) Cancer Res 70 6 2010 2264 2273
98. S. Wee, Z. Jagani, and K.X. Xiang PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 2009 4286 4293